Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo

Authors: Wei Shen, Chun-Yi Wang, Xue-Hu Wang, Zhong-Xue Fu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

Colorectal cancer is a one of the most common alimentary malignancies. Survivin has been proved by many studies to be an ideal target for cancer gene therapy because of its strong anti-apoptotic effect. The reduction of Survivin expression by means of chemically synthesized small interfering RNA or small hairpin RNA expressed from plasmid and resulted growth inhibition of cancer cells had been proved by many studies including ours, but the transfection efficiency was not encouraging. So for the first time we constructed the Survivin shRNA into an oncolytic adenovirus, tested its effects on colorectal cancer cell lines and nude mice xenograft model.

Methods

In this study, we constructed an oncolytic adenovirus with a Survivin targeted small hairpin RNA and a reporter gene (ZD55-Sur-EGFP). The expression of Survivin mRNA and protein were analyzed by RT-PCR and western blot. The cell growth and apoptosis were tested by in vitro cytopathic assay, MTT assay and flow cytometry respectively. The effect of the constructed virus on xenograft model was evaluated by tumor volume and western blot analysis.

Results

ZD55-Sur-EGFP replicated in cancer cells specifically, reduced the expression of Survivin mRNA and protein expression effectively (P < 0.0001), induced cancer cell apoptosis and inhibited SW480 cell growth both in vitro and in vivo significantly.

Conclusion

We conclude Survivin RNA interference combining with oncolytic adenovirus virotherapy to be a promising treatment for colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef
2.
go back to reference Sah NK, Khan Z, Khan GJ, Bisen PS: Structural, functional and therapeutic biology of Survivin. Cancer Lett. 2006, 244 (2): 164-171. 10.1016/j.canlet.2006.03.007.CrossRef Sah NK, Khan Z, Khan GJ, Bisen PS: Structural, functional and therapeutic biology of Survivin. Cancer Lett. 2006, 244 (2): 164-171. 10.1016/j.canlet.2006.03.007.CrossRef
3.
go back to reference Ambrosini G, Adida C, Altieri DC: A noble anti-apoptotic gene, Survivin, is expressed in cancer and lymphoma. Nat. Med. 1997, 3: 917-921. 10.1038/nm0897-917.CrossRef Ambrosini G, Adida C, Altieri DC: A noble anti-apoptotic gene, Survivin, is expressed in cancer and lymphoma. Nat. Med. 1997, 3: 917-921. 10.1038/nm0897-917.CrossRef
4.
go back to reference Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra Cl: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003, 9: 931-46. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra Cl: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003, 9: 931-46.
5.
go back to reference Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D: Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene. 2006, 25: 6968-74. 10.1038/sj.onc.1209676.CrossRef Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D: Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene. 2006, 25: 6968-74. 10.1038/sj.onc.1209676.CrossRef
6.
go back to reference Coma S, et al: Use of siRNAs and antisense oligonucleotides against Survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides. 2004, 14: 100-1351. 10.1089/1545457041526290.CrossRef Coma S, et al: Use of siRNAs and antisense oligonucleotides against Survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides. 2004, 14: 100-1351. 10.1089/1545457041526290.CrossRef
7.
go back to reference Uchida H, et al: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004, 10: 162-71. 10.1016/j.ymthe.2004.05.006.CrossRef Uchida H, et al: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004, 10: 162-71. 10.1016/j.ymthe.2004.05.006.CrossRef
8.
go back to reference Zaffaroni N, Pennati M, Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005, 9: 360-72. 10.1111/j.1582-4934.2005.tb00361.x.CrossRef Zaffaroni N, Pennati M, Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005, 9: 360-72. 10.1111/j.1582-4934.2005.tb00361.x.CrossRef
9.
go back to reference Khuri FR, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000, 6: 879-85. 10.1038/78638.CrossRef Khuri FR, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000, 6: 879-85. 10.1038/78638.CrossRef
10.
go back to reference Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997, 3: 639-45. 10.1038/nm0697-639.CrossRef Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997, 3: 639-45. 10.1038/nm0697-639.CrossRef
11.
go back to reference Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003, 13: 481-9. 10.1038/sj.cr.7290191.CrossRef Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003, 13: 481-9. 10.1038/sj.cr.7290191.CrossRef
12.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRef
13.
go back to reference Bar-Sela G, Haim N: Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol. 2004, 21: 251-4. 10.1385/MO:21:3:251.CrossRef Bar-Sela G, Haim N: Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol. 2004, 21: 251-4. 10.1385/MO:21:3:251.CrossRef
14.
go back to reference Bernhardson BM, Tishelman C, Rutqvist LE: Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage. 2007, 34: 403-12. 10.1016/j.jpainsymman.2006.12.010.CrossRef Bernhardson BM, Tishelman C, Rutqvist LE: Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage. 2007, 34: 403-12. 10.1016/j.jpainsymman.2006.12.010.CrossRef
15.
go back to reference Joosten J, Jager G, Oyen W, Wobbes T, Ruers T: Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol. 2005, 31: 1152-9. 10.1016/j.ejso.2005.07.010.CrossRef Joosten J, Jager G, Oyen W, Wobbes T, Ruers T: Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol. 2005, 31: 1152-9. 10.1016/j.ejso.2005.07.010.CrossRef
16.
go back to reference Gravalos C, García-Sanchez L, Hernandez M, Holgado E, Alvarez N, García-Escobar I, Martínez J, Robles L: Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure?. Clin Colorectal Cancer. 2008, 7: 398-401. 10.3816/CCC.2008.n.053.CrossRef Gravalos C, García-Sanchez L, Hernandez M, Holgado E, Alvarez N, García-Escobar I, Martínez J, Robles L: Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure?. Clin Colorectal Cancer. 2008, 7: 398-401. 10.3816/CCC.2008.n.053.CrossRef
17.
go back to reference Renouf D, Kennecke H, Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 2008, 7: 386-9. 10.3816/CCC.2008.n.051.CrossRef Renouf D, Kennecke H, Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 2008, 7: 386-9. 10.3816/CCC.2008.n.051.CrossRef
18.
go back to reference Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004, 15: 933-9. 10.1093/annonc/mdh217.CrossRef Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004, 15: 933-9. 10.1093/annonc/mdh217.CrossRef
19.
go back to reference Couzin J: Breakthrough of the year. Small RNAs make big splash. Science. 2002, 20 (298): 2296-2297. 10.1126/science.298.5602.2296.CrossRef Couzin J: Breakthrough of the year. Small RNAs make big splash. Science. 2002, 20 (298): 2296-2297. 10.1126/science.298.5602.2296.CrossRef
20.
go back to reference Chen T, Deng C: Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immunopharmacol. 2008, 8: 1006-11. 10.1016/j.intimp.2008.03.004.CrossRef Chen T, Deng C: Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immunopharmacol. 2008, 8: 1006-11. 10.1016/j.intimp.2008.03.004.CrossRef
21.
go back to reference Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, Bai WT, Zhang X: Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol. 2007, 31: 1111-7. Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, Bai WT, Zhang X: Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol. 2007, 31: 1111-7.
22.
go back to reference Li QX, et al: Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006, 5: 860-6.CrossRef Li QX, et al: Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006, 5: 860-6.CrossRef
23.
go back to reference Sun BS, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008, 48: 1834-42. 10.1002/hep.22531.CrossRef Sun BS, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008, 48: 1834-42. 10.1002/hep.22531.CrossRef
24.
go back to reference Charames GS, Bapat B: Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol. 2006, 28: 543-9. Charames GS, Bapat B: Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol. 2006, 28: 543-9.
25.
go back to reference Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005, 26: 741-51. 10.1093/carcin/bgi027.CrossRef Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005, 26: 741-51. 10.1093/carcin/bgi027.CrossRef
26.
go back to reference Hsu KF, Wu CL, Huang SC, Hsieh JL, Huang YS, Chen YF, Shen MR, Chung WJ, Chou CY, Shiau AL: Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther. 2008, 15: 526-34. 10.1038/cgt.2008.37.CrossRef Hsu KF, Wu CL, Huang SC, Hsieh JL, Huang YS, Chen YF, Shen MR, Chung WJ, Chou CY, Shiau AL: Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther. 2008, 15: 526-34. 10.1038/cgt.2008.37.CrossRef
27.
go back to reference Bischoff JR, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996, 274: 373-6. 10.1126/science.274.5286.373.CrossRef Bischoff JR, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996, 274: 373-6. 10.1126/science.274.5286.373.CrossRef
28.
go back to reference Heise CC, Williams AM, Xue S, Propst M, Kirn DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999, 59: 2623-8. Heise CC, Williams AM, Xue S, Propst M, Kirn DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999, 59: 2623-8.
29.
go back to reference Liu TC, Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15: 877-84. 10.1038/gt.2008.72.CrossRef Liu TC, Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15: 877-84. 10.1038/gt.2008.72.CrossRef
30.
go back to reference Wildner O, Blaese RM, Morris JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999, 15 (59): 410-3. Wildner O, Blaese RM, Morris JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999, 15 (59): 410-3.
31.
go back to reference Sagawa T, et al: Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology. 2008, 48: 828-40. 10.1002/hep.22420.CrossRef Sagawa T, et al: Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology. 2008, 48: 828-40. 10.1002/hep.22420.CrossRef
32.
go back to reference Zheng JN, Pei DS, Mao LJ, Liu XY, Mei DD, Zhang BF, Shi Z, Wen RM, Sun XQ: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 2009, 16: 20-32. 10.1038/cgt.2008.61.CrossRef Zheng JN, Pei DS, Mao LJ, Liu XY, Mei DD, Zhang BF, Shi Z, Wen RM, Sun XQ: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 2009, 16: 20-32. 10.1038/cgt.2008.61.CrossRef
33.
go back to reference Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, Li N, Wang YG: Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carring MDA-7/IL-24. Acta Pharmacol Sin. 2009, 30: 467-477. 10.1038/aps.2009.16.CrossRef Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, Li N, Wang YG: Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carring MDA-7/IL-24. Acta Pharmacol Sin. 2009, 30: 467-477. 10.1038/aps.2009.16.CrossRef
Metadata
Title
Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo
Authors
Wei Shen
Chun-Yi Wang
Xue-Hu Wang
Zhong-Xue Fu
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-81

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine